Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Wolfgang Dohle

Research Associate

My research focuses on anti-cancer drug design using synthetic organic chemistry as the main tool. Tetrahydroisoquinoline derivatives with excellent physicochemical properties were developed as a new class of microtubule disruptors showing very good activity against various cancer cells lines including some taxane-resistant ones.

One of our most potent compound to date, STX3451 could also provide a new approach for inducing cell death and lowering tumour burden in NF1 and other hormone responsive cancers with limited treatment options. More recently, my research focus has shifted towards the synthesis of anti-bacterial compounds and inositol adenophostin derivatives.

Key publications

Recent publications

More publications